Loading company
NeuroSense Therapeutics Ltd.
NRSN · Nasdaq · ·
$4.74-3.8%Sep 29 close
- 1M
- -43.6%
- 6M
- -67.6%
- 1Y
- -81.0%
NRSN · Nasdaq · ·
$4.74-3.8%Sep 29 close
From the company’s own 6-K filing.
“Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within approximately 3 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K NeuroSense Therapeutics Ltd. filed on September 25, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
NeuroSense Therapeutics Ltd. has no earnings call transcript available.